Since we previously demonstrated that miR-218-5p impairs Parkin-mediated mitophagy in HEK293 [19], and that its expression is inversely correlated with poor survival in BC patients [17], and since miRNA-based therapies are promising in cancer [23], we hypothesised that miR-218-5p expression could be useful to inhibit DXR-dependent mitophagy in BC cells, thus improving drug efficacy. Here, PRKN is linked to cancer.